{"id":908802,"date":"2025-11-12T10:30:54","date_gmt":"2025-11-12T15:30:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/"},"modified":"2025-11-12T10:30:54","modified_gmt":"2025-11-12T15:30:54","slug":"neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/","title":{"rendered":"NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CARMEL, Ind., Nov.  12, 2025  (GLOBE NEWSWIRE) &#8212; NeurAxis, Inc. (\u201cNeurAxis\u201d or the \u201cCompany\u201d) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 566,000 total covered lives, in Michigan. With this addition, approximately 82% of commercially insured pediatric beneficiaries in Michigan now have access to PENFS under medical policy. This expansion increases NeurAxis\u2019 total national coverage to roughly 55 million total lives, with additional payer decisions from major insurers expected in the coming months.<\/p>\n<p align=\"justify\">NeurAxis\u2019 proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia (nausea symptoms) in patients 8 years and older. IB-Stim is a non-invasive neuromodulation device that gently stimulates cranial nerve bundles in the ear to help regulate pain signaling between the gut and the brain. Currently, no FDA-approved drug therapies exist for pediatric patients with abdominal pain-related disorders of gut-brain interaction (DGBIs), a significant unmet medical need. In the absence of approved options, off-label prescription drugs are often used, despite limited efficacy data and potential safety concerns\u2014underscoring IB-Stim\u2019s unique position as the only FDA-cleared therapy specifically designed for this large and underserved pain related patient population.<\/p>\n<p align=\"justify\">\u201cWe remain focused on expanding insurance coverage for IB-Stim to make this much-needed therapy for abdominal pain associated with IBS and Functional Dyspepsia more accessible and affordable for patients,\u201d said Brian Carrico, CEO of NeurAxis. \u201cOur payer engagement strategy is progressing well, with several of the nation\u2019s largest insurers now in active discussions as they approach policy review cycles over the next eight months. With a Category I CPT code taking effect January 1, 2026, and our proprietary PENFS technology recognized in leading clinical practice guidelines, we believe NeurAxis is positioned for meaningful revenue growth and margin expansion. Supported by a strengthened balance sheet, we are ready to capitalize on the accelerating demand ahead.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About NeurAxis, Inc.<\/strong><br \/>\n        <br \/>NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim\u2122 therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim\u2122 is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional dyspepsia in patients 8 years and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PrDpA6UOiuCG-2YJPmf0ik_ISsOHA5vyq8DdofkDLFp1mabBSMer5qRX-Si1OedzvBPmF1hOtPwcMj-6sGasiOIcjOiWjeDks0gK1VutCp948NKUn1wPHIOK8iAPT3HkzFY-FC5EYAeubY9jmGKARtLt961wI2rMANfBmig3iv04jIh_1d_2a8mLmTCRt0mfwwhAtozcFhNzbdUlC1cxiBhzHF2RloTGzZF4NMn0bh7noi5D2Ow0KhOl-BFBhGIx\" rel=\"nofollow\" target=\"_blank\">http:\/\/neuraxis.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements <\/strong><br \/>\n        <br \/>Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management\u2019s current assumptions and expectations of future events and trends, which affect or may affect the Company\u2019s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company\u2019s stock, public health issues or other events, the Company\u2019s compliance with applicable laws, the results of the Company\u2019s clinical trials and perceptions thereof, the results of submissions to the FDA, and factors described in the Risk Factors section of NeurAxis\u2019s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.<\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Company<\/strong><br \/>\n        <br \/>\n        <strong>NeurAxis, Inc.<\/strong><br \/>\n        <br \/>info@neuraxis.com<br \/>For contraindications, precautions, warnings, and IFU, please see: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J9G8f0PVpPjPE-osqWG8k7KJHC5Xxlogs91dAl9LAc80y36ObgP-4lSAybDlnQsKTMtIn5gpG6CwGIUsod5m6qiCVhAAwzwOccrFocA8d0TitVcQ3FsP9E3ljxZlRxrEj-NpoTvUGSwZ2tAevM9Gig==\" rel=\"nofollow\" target=\"_blank\">https:\/\/ibstim.com\/important-information\/<\/a>.<\/p>\n<p>\n        <strong>Investor Relations<\/strong><br \/>\n        <br \/>Lytham Partners<br \/>Ben Shamsian<br \/>646-829-9701<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dUkdmEpjqLm0DwzujcjRuXkMoN6FjHdrn-YNUL2KNFn6zBO108ENlgglbbxKnmDQ4r-N8E8NwL05CM5lx7VBzd2Qli-sRyiSBJCq9rW1EGx3pjZbc4C8CjuLSoHNMBCI\" rel=\"nofollow\" target=\"_blank\">shamsian@lythampartners.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzY0OCM3MjU4MTYxIzIyNTIyNDI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDA0Y2Y0ZGMtMTFkYi00MzNjLWIzOTItMjM1ZDEzNTQyOTE1LTEyNjM3OTUtMjAyNS0xMS0xMi1lbg==\/tiny\/NeurAxis-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CARMEL, Ind., Nov. 12, 2025 (GLOBE NEWSWIRE) &#8212; NeurAxis, Inc. (\u201cNeurAxis\u201d or the \u201cCompany\u201d) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 566,000 total covered lives, in Michigan. With this addition, approximately 82% of commercially insured pediatric beneficiaries in Michigan now have access to PENFS under medical policy. This expansion increases NeurAxis\u2019 total national coverage to roughly 55 million total lives, with additional payer decisions from major insurers expected in the coming months. NeurAxis\u2019 proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-908802","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARMEL, Ind., Nov. 12, 2025 (GLOBE NEWSWIRE) &#8212; NeurAxis, Inc. (\u201cNeurAxis\u201d or the \u201cCompany\u201d) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 566,000 total covered lives, in Michigan. With this addition, approximately 82% of commercially insured pediatric beneficiaries in Michigan now have access to PENFS under medical policy. This expansion increases NeurAxis\u2019 total national coverage to roughly 55 million total lives, with additional payer decisions from major insurers expected in the coming months. NeurAxis\u2019 proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and &hellip; Continue reading &quot;NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-12T15:30:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzY0OCM3MjU4MTYxIzIyNTIyNDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives\",\"datePublished\":\"2025-11-12T15:30:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\\\/\"},\"wordCount\":766,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3MzY0OCM3MjU4MTYxIzIyNTIyNDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\\\/\",\"name\":\"NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3MzY0OCM3MjU4MTYxIzIyNTIyNDI=\",\"datePublished\":\"2025-11-12T15:30:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3MzY0OCM3MjU4MTYxIzIyNTIyNDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3MzY0OCM3MjU4MTYxIzIyNTIyNDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/","og_locale":"en_US","og_type":"article","og_title":"NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives - Market Newsdesk","og_description":"CARMEL, Ind., Nov. 12, 2025 (GLOBE NEWSWIRE) &#8212; NeurAxis, Inc. (\u201cNeurAxis\u201d or the \u201cCompany\u201d) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 566,000 total covered lives, in Michigan. With this addition, approximately 82% of commercially insured pediatric beneficiaries in Michigan now have access to PENFS under medical policy. This expansion increases NeurAxis\u2019 total national coverage to roughly 55 million total lives, with additional payer decisions from major insurers expected in the coming months. NeurAxis\u2019 proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and &hellip; Continue reading \"NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-12T15:30:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzY0OCM3MjU4MTYxIzIyNTIyNDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives","datePublished":"2025-11-12T15:30:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/"},"wordCount":766,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzY0OCM3MjU4MTYxIzIyNTIyNDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/","name":"NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzY0OCM3MjU4MTYxIzIyNTIyNDI=","datePublished":"2025-11-12T15:30:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzY0OCM3MjU4MTYxIzIyNTIyNDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzY0OCM3MjU4MTYxIzIyNTIyNDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=908802"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908802\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=908802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=908802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=908802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}